We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Radiation-Free Approach Images Molecules in Brain

By MedImaging International staff writers
Posted on 22 Dec 2016
A new study describes how protein-based sensors can cause blood vessels to dilate near their targets, allowing them to be detected by magnetic resonance imaging (MRI).

Developed by researchers at the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA), the probes are based on a modified calcitonin gene-related peptide (CGRP), which is active primarily during migraines or inflammation. The novel CGRP-related peptide is used to artificially activate vasculature dilation at nanomolar concentrations, thus enhancing an endogenous multimodal tissue contrast which can then be readily measured by optical and MRI scans in order to determine where the proteases were detected.

Image: CGRP-based sensors dilate blood vessels in the brain to make them visible on MRI (Photo courtesy of Alan Jasanoff / MIT).
Image: CGRP-based sensors dilate blood vessels in the brain to make them visible on MRI (Photo courtesy of Alan Jasanoff / MIT).

In order to direct the CGRP-related peptide to their targets, they have been engineered so that they are trapped within a protein enclosure that keeps them from interacting with blood vessels. But when the peptides encounter proteases in the brain, the enclosures are disrupted, releasing CGRP, which causes nearby blood vessels to dilate. The researchers are now working on adapting the design to monitor neurotransmitters by modifying the enclosures surrounding the CGRP so that they can be removed by interaction with a specific neurotransmitter. The study was published on December 2, 2016, in Nature Communications.

“Currently the gold standard approach to imaging molecules in the brain is to tag them with radioactive probes. However, these probes offer low resolution and they can't easily be used to watch dynamic events,” said lead author professor of biological engineering Alan Jasanoff, PhD. “This is an idea that enables us to detect molecules that are in the brain at biologically low levels, and to do that with these imaging agents or contrast agents that can ultimately be used in humans.”

The vasculature is one of the most potent endogenous contrast sources available to imaging modalities. Vascular hemodynamic changes can be evoked by a variety of chemical species, many of which act at nanomolar concentrations. The changes in blood volume, flow, or oxygenation are robustly detectable by MRI, optical, and ultrasound-based noninvasive imaging, as well as by positron emission tomography (PET), single photon computed tomography, and X-ray imaging with intravascular tracers.

Related Links:
Massachusetts Institute of Technology


Radiation Therapy Treatment Software Application
Elekta ONE
Multi-Use Ultrasound Table
Clinton
New
HF Stationary X-Ray Machine
TR20G
Ultra-Flat DR Detector
meX+1717SCC

Latest General/Advanced Imaging News

AI-Powered Imaging System Improves Lung Cancer Diagnosis

AI Model Significantly Enhances Low-Dose CT Capabilities

Ultra-Low Dose CT Aids Pneumonia Diagnosis in Immunocompromised Patients